The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Rationale:
- As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Durvalumab with tremelimumab within its marketing authorisation for treating limited-stage small-cell lung cancer after chemoradiation. Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be rescheduled to align with latest regulatory expectations and an update on the revised timelines will be provided when further information is available.
- Process:
- TA
- ID number:
- 5097
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 December 2025 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 23 December 2024 | Note - Note added to the project documents |
| 17 July 2023 | Note - Note added to the project documents |
| 28 November 2022 | Awaiting development |
| 28 November 2022 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual